Advertisement

Topics

M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer

2018-02-21 19:15:09 | BioPortfolio

Published on BioPortfolio: 2018-02-21T19:15:09-0500

Clinical Trials [722 Associated Clinical Trials listed on BioPortfolio]

M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)

The goal of this clinical research study is to learn if giving M7824 (MSB0011359C) to patients with Stage II or III HER2+ breast cancer who are scheduled to receive chemotherapy and have s...

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Background: Pancreas cancer ranks 4th in all cancer-related deaths in the U.S. Gemcitabine is a standard treatment for it. M7824 blocks a pathway that prevents the immune system from effe...

M7824 and Eribulin Mesylate in Treating Participants With Metastatic Triple Negative Breast Cancer

This phase Ib trial studies best dose and side effects of eribulin mesylate when given together with anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) in treating participants with triple...

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Background: Small cell lung cancer (SCLC) is an aggressive cancer. People with SCLC tend to be respond well to chemotherapy at first, but become resistant to treatment after a few months....

PubMed Articles [1658 Associated PubMed Articles listed on BioPortfolio]

Identification of prognostic miRNA biomarkers for predicting overall survival of colon adenocarcinoma and bioinformatics analysis: A study based on The Cancer Genome Atlas database.

This study was conducted to identify the prognostic microRNA (miRNA) for the prediction of survival in colon adenocarcinoma (CA).

Impact of Tumor Deposits on Oncologic Outcomes in Stage III Colon Cancer.

The prognosis of tumor deposits in stage III colon adenocarcinoma is poorly described.

Identification of long noncoding RNAs biomarkers for diagnosis and prognosis in patients with colon adenocarcinoma.

In the study, we aimed to find key long noncoding RNAs (lncRNAs) significantly associated with the diagnosis of colon adenocarcinoma (COAD) and lncRNA signatures to provide survival risk prognosis for...

Sporadic colon cancer in Lebanon: A clinicopathological study.

Colon cancer is a heavy public health burden. No data has been previously published on colon cancer epidemiology in Lebanon. The objective of this study was to report the clinical and pathological fea...

Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model.

In sporadic colon tumors, multistep process of well-known genetic alterations accelerates carcinogenesis; however, this does not appear to be the case in inflammation-related ones. We previously estab...

Medical and Biotech [MESH] Definitions

The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.

A lesion with cytological characteristics associated with invasive adenocarcinoma but the tumor cells are confined to the GLANDULAR EPITHELIAL CELLS of origin. Adenocarcinoma in situ of the CERVIX and the LUNG are the most common.

The segment of LARGE INTESTINE between ASCENDING COLON and DESCENDING COLON. It passes from the RIGHT COLIC FLEXURE across the ABDOMEN, then turns sharply at the left colonic flexure into the descending colon.

The segment of LARGE INTESTINE between TRANSVERSE COLON and the SIGMOID COLON.

A segment of the COLON between the RECTUM and the descending colon.

More From BioPortfolio on "M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial